Affinia Therapeutics to Present Preclinical Data on Novel AAV Capsids at the 30th European Society of Gene and Cell Therapy 2023 Annual Congress
24 Oct 2023
Gene Therapy
WALTHAM, Mass., Oct. 24, 2023 /PRNewswire/ -- Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that the company will present preclinical data on its novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS) in a poster session at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, being held October 24-27, 2023, in Brussels, Belgium.
The poster presentation details are listed below and the full program can be found on the ESGCT website at www.esgctcongress.com.
Title: Engineered AAV capsids with significantly improved muscle and CNS tropism plus reduced liver and DRG expression compared to AAV9
Abstract Number: P084
Date: October 25, 2023, 6:15-7:30 PM CEST and October 26, 2023, 7:30-8:30 PM CEST
Presenter: John Reece-Hoyes, Ph.D., Senior Director, Head of Vector Biology, Affinia
About Affinia Therapeutics
Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics' proprietary Affinia Rationally designed Therapeutics (ART) platform consists of three pillars intended to synergistically improve the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches. For more information, visit https://www.affiniatx.com.
SOURCE Affinia Therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.